158 related articles for article (PubMed ID: 37349101)
21. Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
Varol U; Karaca B; Cakar B; Sezgin C; Karabulut B; Uslu R
Am J Clin Oncol; 2013 Aug; 36(4):388-91. PubMed ID: 22643568
[TBL] [Abstract][Full Text] [Related]
22. Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
Shitara K; Yuki S; Yamazaki K; Naito Y; Fukushima H; Komatsu Y; Yasui H; Takano T; Muro K
J Cancer Res Clin Oncol; 2013 Apr; 139(4):595-603. PubMed ID: 23250506
[TBL] [Abstract][Full Text] [Related]
23. High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapy.
Yamada Y; Fujii H; Ohata K; Kato-Hayashi H; Watanabe D; Ishihara T; Uemura S; Iwashita T; Imai H; Matsuhashi N; Takahashi T; Sugiyama T; Shimizu M; Yoshida K; Suzuki A
Med Oncol; 2019 Jun; 36(7):63. PubMed ID: 31161433
[TBL] [Abstract][Full Text] [Related]
24. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
25. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
[TBL] [Abstract][Full Text] [Related]
26. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
Mross K; Steinbild S; Baas F; Gmehling D; Radtke M; Voliotis D; Brendel E; Christensen O; Unger C
Eur J Cancer; 2007 Jan; 43(1):55-63. PubMed ID: 17095207
[TBL] [Abstract][Full Text] [Related]
27. Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases.
Litvak DA; Wood TF; Tsioulias GJ; Chung M; Chawla SP; Foshag LJ; Morton DL; Ramming KP; Bilchik AJ
Ann Surg Oncol; 2002 Mar; 9(2):148-55. PubMed ID: 11888871
[TBL] [Abstract][Full Text] [Related]
28. Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.
Wulaningsih W; Wardhana A; Watkins J; Yoshuantari N; Repana D; Van Hemelrijck M
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008593. PubMed ID: 26869023
[TBL] [Abstract][Full Text] [Related]
29. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
Ychou M; Viret F; Kramar A; Desseigne F; Mitry E; Guimbaud R; Delpero JR; Rivoire M; Quénet F; Portier G; Nordlinger B
Cancer Chemother Pharmacol; 2008 Jul; 62(2):195-201. PubMed ID: 17901955
[TBL] [Abstract][Full Text] [Related]
30. Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience.
Vincenzi B; Imperatori M; Picardi A; Vespasiani Gentilucci U; Gallo P; Fausti V; Spalato Ceruso M; Santini D; Tonini G
Expert Rev Anticancer Ther; 2015; 15(8):971-6. PubMed ID: 26112080
[TBL] [Abstract][Full Text] [Related]
31. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.
van Hazel GA; Pavlakis N; Goldstein D; Olver IN; Tapner MJ; Price D; Bower GD; Briggs GM; Rossleigh MA; Taylor DJ; George J
J Clin Oncol; 2009 Sep; 27(25):4089-95. PubMed ID: 19652069
[TBL] [Abstract][Full Text] [Related]
32. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
[TBL] [Abstract][Full Text] [Related]
33. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Fernandez FG; Ritter J; Goodwin JW; Linehan DC; Hawkins WG; Strasberg SM
J Am Coll Surg; 2005 Jun; 200(6):845-53. PubMed ID: 15922194
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
Liu JH; Hsieh YY; Chen WS; Hsu YN; Chau GY; Teng HW; King KL; Lin TC; Tzeng CH; Lin JK
Int J Colorectal Dis; 2010 Oct; 25(10):1243-9. PubMed ID: 20574727
[TBL] [Abstract][Full Text] [Related]
35. Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases.
Viganò L; Capussotti L; Barroso E; Nuzzo G; Laurent C; Ijzermans JN; Gigot JF; Figueras J; Gruenberger T; Mirza DF; Elias D; Poston G; Letoublon C; Isoniemi H; Herrera J; Sousa FC; Pardo F; Lucidi V; Popescu I; Adam R
Ann Surg Oncol; 2012 Sep; 19(9):2786-96. PubMed ID: 22622469
[TBL] [Abstract][Full Text] [Related]
36. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.
Said R; Kurzrock R; Naing A; Hong DS; Fu S; Piha-Paul SA; Wheler JJ; Janku F; Kee BK; Bidyasar S; Lim J; Wallace M; Tsimberidou AM
Invest New Drugs; 2015 Aug; 33(4):911-20. PubMed ID: 25990659
[TBL] [Abstract][Full Text] [Related]
37. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
38. Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.
Cai X; Cao W; Ding H; Liu T; Zhou X; Wang M; Zhong M; Zhao Z; Xu Q; Wang L
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1579-89. PubMed ID: 23892411
[TBL] [Abstract][Full Text] [Related]
39. Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis.
Kanbayashi Y; Ishikawa T; Kanazawa M; Nakajima Y; Tabuchi Y; Kawano R; Yoshioka T; Yoshida N; Hosokawa T; Takayama K; Taguchi T
Med Oncol; 2018 Apr; 35(6):82. PubMed ID: 29705823
[TBL] [Abstract][Full Text] [Related]
40. CT-based radiomics for the identification of colorectal cancer liver metastases sensitive to first-line irinotecan-based chemotherapy.
Qi W; Yang J; Zheng L; Lu Y; Liu R; Ju Y; Niu T; Wang D
Med Phys; 2023 May; 50(5):2705-2714. PubMed ID: 36841949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
